The Ratio of C-Reactive Protein/Albumin is a Novel Inflammatory Predictor of Overall Survival in Cisplatin-Based Treated Patients with Metastatic Nasopharyngeal Carcinoma

Table 1

Baseline clinical features of 148 patients with metastatic nasopharyngeal carcinoma.

Characteristic	Number (%)	CRP/Alb < 0.189, number (%)	CRP/Alb ≥ 0.189, number (%)	value
Gender (male/female)	124/24 (83.8/16.2)	63/15 (80.8/19.2)	61/9 (87.1/12.9)	0.373
Age, years (median/range)	45/24–72	45/26–70	43.5/24–72	0.765
KPS (median/range)	90/60–100	90/60–100	90/60–100	0.276
Number of involved sites (one/multiple)	69/79 (46.6/53.4)	42/36 (53.8/46.2)	27/43 (38.6/61.4)	0.071
Synchronous metastasis (yes/no)	43/105 (29.1/70.9)	20/58 (25.6/74.4)	23/47 (32.9/67.1)	0.368
Liver metastasis (yes/no)	56/92 (37.8/62.2)	28/50 (35.9/64.1)	28/42 (40/60)	0.615
Lung metastasis (yes/no)	69/79 (46.6/53.4)	38/40 (48.7/51.3)	31/39 (44.3/55.7)	0.623
Bone metastasis (yes/no)	61/87 (41.2/58.8)	28/50 (35.9/64.1)	33/37 (47.1/52.9)	0.184
Smoking (yes/no)	68/80 (45.9/54.1)	36/42 (42.1/53.8)	32/38 (45.7/54.3)	1.000
GPS (0/1/2)	88/46/14 (59.5/31.1/9.4)	52/20/6 (66.7/25.6/7.7)	36/26/8 (51.4/37.1/11.4)	0.169
Serum LDH, U/L (median/range)	202.5/25–2975	179.5/122–2821	230/25–2975	0.069
EBV-DNA, copies/mL (median/range)	4.82 × 104/0–9.13 × 107	3.49 × 104/0–9.87 × 106	5.32 × 105/0–9.13 × 107	0.013
Chemotherapy regimen (TP/PF/TPF)	12/45/91 (8.1/30.4/61.5)	7/26/45 (9/33.3/57.7)	5/19/46 (7.2/27.1/65.7)	0.605
Treatment response (CR + PR/PD + SD)	107/41 (72.3/27.7)	59/19 (75.6/24.4)	48/22 (68.6/31.4)	0.363
NLR (median/range)	3.3/1–35.2	2.8/1–14	4/1–35.2	0.001
PLR (median/range)	181/56.4–820	161/88–735	231/56.4–820	0.001
Hemoglobin, g/L (median/range)	131/43–171	132/43–171	123/82–162	0.019

CRP/Alb: C-reactive protein/albumin ratio; KPS: Karnofsky Performance Score; GPS: Glasgow Prognostic Score; NLR: neutrophil to lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; .